Meghana Chalasani leads the Science Strategies program in the Office of New Drugs in FDA’s Center for Drug Evaluation and Research. She also manages the New Drug Regulatory Program’s Advisory Committee modernization effort. Previously, Meghana worked closely on CDER’s Patient-Focused Drug Development initiatives to facilitate the incorporation of patient and caregiver input into decision-making. Prior to joining the FDA, Meghana worked on Capitol Hill and for FasterCures. She also has a strong biomedical research background in genomic medicine and infectious diseases. Meghana holds a master’s in Health Policy and Management from Columbia University and a bachelor’s in Medicine, Health and Society from Vanderbilt University.